TY - JOUR T1 - Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm SP - e1 LP - e1 DO - 10.1136/ejhpharm-2020-002609 VL - 29 IS - 3 AU - Andrea Messori AU - Laura Bartoli AU - Daniele Mengato AU - Marco Chiumente Y1 - 2022/05/01 UR - http://ejhp.bmj.com/content/29/3/e1.abstract N2 - The TRANSCEND trial1 studied a cohort of more than 250 patients with relapsed/refractory non-Hodgkin's lymphoma treated with the chimeric antigen receptor T-cell (CART) product, lisocabtagene maraleucel. This trial enrolled a high number of patients and included a relatively long follow-up (36 months).Estimating the gain in overall survival (OS) for CART patients versus non-CART controls suffers from the lack of long-term survival information for CART. One advantage of the TRANSCEND trial is the availability of survival results at 36 months; this allows us to reliably determine the survival gain. To carry out this estimation, we kept in mind that the restricted mean survival time (RMST) is recognised to be the best outcome measure for managing long-term … ER -